Kazia Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KZIA research report →
Companywww.kaziatherapeutics.com
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.
- CEO
- John Edwin Friend
- IPO
- 1999
- Employees
- 9
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $21.01M
- P/E
- -2.54
- P/S
- 1490.01
- P/B
- 1.22
- EV/EBITDA
- 2.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -92086.45%
- Net Margin
- -113004.58%
- ROE
- -116.86%
- ROIC
- -36.21%
Growth & Income
- Revenue
- $42.00K · -98.18%
- Net Income
- $-20,702,000 · 22.69%
- EPS
- $-18.90 · 65.64%
- Op Income
- $-14,217,000
- FCF YoY
- -38.59%
Performance & Tape
- 52W High
- $17.40
- 52W Low
- $3.30
- 50D MA
- $10.24
- 200D MA
- $8.42
- Beta
- 2.23
- Avg Volume
- 212.65K
Get TickerSpark's AI analysis on KZIA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 13, 26 | Rao Sudha | other | 0 |
| Mar 18, 26 | Friend John E. II | other | 30,000 |
| Mar 18, 26 | Cain David | other | 5,000 |
| Mar 18, 26 | Cain David | other | 100,000 |
| Mar 18, 26 | Cain David | other | 100,000 |
| Mar 18, 26 | Cain David | other | 400,000 |
| Mar 18, 26 | Coffey Steven R. S. | other | 0 |
| Mar 18, 26 | Coffey Steven R. S. | other | 1,000 |
| Mar 18, 26 | Coffey Steven R. S. | other | 75,000 |
| Mar 18, 26 | Coffey Steven R. S. | other | 1,122 |
Our KZIA Coverage
We haven't published any research on KZIA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KZIA Report →